STOCKHOLM – October 10, 2024 – Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology received an honorable mention by the Royal Swedish Academy of Engineering Sciences (IVA) during the Smart Industry business competition 2024 during the award ceremony on October 9 in Gothenburg.
“Inify receives an honorable mention in the Smart Industry business competition 2024 for their ultramodern laboratory that combines an industrial approach with innovations within healthcare processes. Their technology is based on niche digital applications with unique components that enable advanced and vital services, with guaranteed response times within cancer diagnostics and tissue processing”.
The Smart Industry competition is aimed at small and medium-sized enterprises that take advantage of the opportunities offered by digitalisation in a smart and innovative way, leading to clear improvements in resource efficiency or climate impact. Finalists and winners are chosen based on how well the company can show effects and results within digital development, how digitalisation has been utilized to do something unexpected as well as how the company has contributed to the UN sustainability goals (SDGs).
“We see the nomination in the Smart Industry business competition 2024 and this honorable mention as an acknowledgement to our innovation culture that creates value for the healthcare system, patients and society”, says Fredrik Palm, CEO of Inify Laboratories AB.
For further information, please contact CEO Fredrik Palm, fredrik.palm@inify.com, or visit https://www.inify.com
###
Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system. The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision, with 40 years of experience within digital imaging for medical applications. It is listed on Euronext Growth Oslo under the ticker INIFY.
